Statement on analgesic nephropathy.
D000700:Analgesics / Q000009:adverse effects*; D000818:Animals; D001241:Aspirin / Q000009:adverse effects; D001315:Australia; D002110:Caffeine / Q000009:adverse effects; D004348:Drug Labeling; D004335:Drug and Narcotic Control; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000473:pathology; D007681:Kidney Papillary Necrosis / Q000139:chemically induced / Q000473:pathology; D008297:Male; D010615:Phenacetin / Q000009:adverse effects; D012106:Research; D012737:Sex Factors; D019966:Substance-Related Disorders
D000700:Analgesics; D002110:Caffeine; D010615:Phenacetin; D001241:Aspirin